-
公开(公告)号:US20090203777A1
公开(公告)日:2009-08-13
申请号:US11911391
申请日:2006-04-12
申请人: Henry Luke Danahay , Darren Mark Legrand , David C. Tully , Jennifer Leslie Harris , Silvia Heuerding , Dilraj Singh , Janet Catherine Maas , Juergen Roettele , Jean-Louis Reber , Stephanie Monnier
发明人: Henry Luke Danahay , Darren Mark Legrand , David C. Tully , Jennifer Leslie Harris , Silvia Heuerding , Dilraj Singh , Janet Catherine Maas , Juergen Roettele , Jean-Louis Reber , Stephanie Monnier
IPC分类号: A61K31/235 , C07C279/18
CPC分类号: A61K9/19 , C07C279/18
摘要: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).
摘要翻译: 本发明描述了新的药学上可接受的盐形式的camostat,冻干方法,掩味制剂,雾化制剂以及前述治疗呼吸系统疾病,特别是囊性纤维化和慢性阻塞性肺病(COPD) 。
-
公开(公告)号:US20120208882A1
公开(公告)日:2012-08-16
申请号:US13372984
申请日:2012-02-14
申请人: Henry Luke Danahay , Darren Mark LeGrand , David C. Tully , Jennifer Leslie Harris , Silvia Heuerding , Dilraj Singh , Janet Catherine Maas , Juergen Roettele , Jean-Louis Reber , Stéphanie Monnier
发明人: Henry Luke Danahay , Darren Mark LeGrand , David C. Tully , Jennifer Leslie Harris , Silvia Heuerding , Dilraj Singh , Janet Catherine Maas , Juergen Roettele , Jean-Louis Reber , Stéphanie Monnier
IPC分类号: A61K31/245 , A61P11/00
CPC分类号: A61K9/19 , C07C279/18
摘要: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).
摘要翻译: 本发明描述了新的药学上可接受的盐形式的camostat,冻干方法,掩味制剂,雾化制剂以及前述治疗呼吸系统疾病,特别是囊性纤维化和慢性阻塞性肺病(COPD) 。
-
公开(公告)号:US20120289536A1
公开(公告)日:2012-11-15
申请号:US13489396
申请日:2012-06-05
IPC分类号: A61K31/436 , A61P29/00 , A61P37/06
CPC分类号: A61K9/0056 , A61K9/145 , A61K9/146 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/435 , A61K31/445
摘要: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
摘要翻译: 一种药物组合物,其包含大环内酯固体分散体,崩解剂和胶态二氧化硅,其中所述组合物包含1至5重量%的胶态二氧化硅。
-
公开(公告)号:US20110306630A1
公开(公告)日:2011-12-15
申请号:US13158921
申请日:2011-06-13
IPC分类号: A61K31/436 , A61P37/06
CPC分类号: A61K9/0056 , A61K9/145 , A61K9/146 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/435 , A61K31/445
摘要: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
摘要翻译: 一种药物组合物,其包含大环内酯固体分散体,崩解剂和胶态二氧化硅,其中所述组合物包含1至5重量%的胶态二氧化硅。
-
公开(公告)号:US08617598B2
公开(公告)日:2013-12-31
申请号:US13489396
申请日:2012-06-05
IPC分类号: A61K31/436 , A61K9/20
CPC分类号: A61K9/0056 , A61K9/145 , A61K9/146 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/435 , A61K31/445
摘要: A pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight.
摘要翻译: 一种药物组合物,其包含大环内酯固体分散体,崩解剂和胶态二氧化硅,其中所述组合物包含1至5重量%的胶态二氧化硅。
-
公开(公告)号:US20100221331A1
公开(公告)日:2010-09-02
申请号:US12776711
申请日:2010-05-10
IPC分类号: A61K9/20 , A61K31/436 , A61P37/06 , A61P29/00
CPC分类号: A61K9/0056 , A61K9/145 , A61K9/146 , A61K9/2009 , A61K9/2027 , A61K9/2077 , A61K31/435 , A61K31/445
摘要: The present invention provides a pharmaceutical composition comprising a macrolide solid dispersion, a disintegrant and colloidal silicon dioxide. The composition comprises 1 to 5% colloidal silicon dioxide by weight.
摘要翻译: 本发明提供包含大环内酯固体分散体,崩解剂和胶态二氧化硅的药物组合物。 该组合物包含1至5重量%的胶态二氧化硅。
-
-
-
-
-